Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Larson

Showing results (191-200 of 208) with videos related to

Pageof 21
Sort By:
Blood|May 26, 1999
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experienceM Wetzler, R K Dodge, K Mrózek, et al.
Blood|May 23, 2001
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)M R Baer, C C Stewart, R K Dodge, et al.
Leukemia|August 30, 2002
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)R A Larson, M Boogaerts, E Estey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B StudyK Mrózek, T W Prior, C Edwards, et al.
Annals of Hematology|May 6, 2004
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461C D Bloomfield, A S Ruppert, K Mrózek, et al.
Leukemia|September 15, 2016
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)W Blum, B L Sanford, R Klisovic, et al.
Leukemia|February 4, 2016
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialA Hochhaus, G Saglio, T P Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapseE L Sievers, R A Larson, E A Stadtmauer, et al.
Leukemia|April 22, 2006
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignanciesM L Slovak, H Gundacker, C D Bloomfield, et al.
Leukemia|July 6, 2012
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II studyF J Giles, P D le Coutre, J Pinilla-Ibarz, et al.
Pageof 21

Showing results (191-200 of 208) with videos related to

Sort By:
Pageof 21
Blood|May 26, 1999
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experienceM Wetzler, R K Dodge, K Mrózek, et al.
Blood|May 23, 2001
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)M R Baer, C C Stewart, R K Dodge, et al.
Leukemia|August 30, 2002
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)R A Larson, M Boogaerts, E Estey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B StudyK Mrózek, T W Prior, C Edwards, et al.
Annals of Hematology|May 6, 2004
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461C D Bloomfield, A S Ruppert, K Mrózek, et al.
Leukemia|September 15, 2016
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)W Blum, B L Sanford, R Klisovic, et al.
Leukemia|February 4, 2016
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialA Hochhaus, G Saglio, T P Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapseE L Sievers, R A Larson, E A Stadtmauer, et al.
Leukemia|April 22, 2006
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignanciesM L Slovak, H Gundacker, C D Bloomfield, et al.
Leukemia|July 6, 2012
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II studyF J Giles, P D le Coutre, J Pinilla-Ibarz, et al.
Pageof 21